Publication: 2042

Publication: 2042

Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.

PubMed

DOI

Google Scholar

Citation:: J Clin Oncol vol 21 (6) 976-83

Year:: 2003
Type:: Manuscript
Funding:: NCTN
Endpoint:: Primary
Analysis:: Primary
Data Sharing:: No-Data-Sharing
Status:: Presented/Published
Citation Status:: pub

Note:

Methodological:: No
Biospecimen:: No
SDC:: No
Book Volume:

Parents:: None
Children:: None

Program:: OGC
Primary Committee:: Breast
Sec. Committees:

Pharmas:
Grants:: CA31946

Corr. Author:
Authors:: I Craig Henderson Donald A Berry George D Demetri Constance T Cirrincione Lori J Goldstein Silvana Martino James N Ingle M Robert Cooper Daniel F Hayes Katherine H Tkaczuk Gini Fleming James F Holland David B Duggan John T Carpenter Emil Frei Richard L Schilsky William C Wood Hyman B Muss Larry Norton

Networks:

Study: CALGB-9344
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:: 3

Keywords:: Adult, Aged, Antibiotics, Antineoplastic, Antineoplastic Agents, Phytogenic, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Disease-Free Survival, Dose-Response Relationship, Drug, Doxorubicin, Female, Humans, Lymphatic Metastasis, Middle Aged, Paclitaxel, Proportional Hazards Models, Treatment Outcome